PROVIDENCE, R.I., Aug. 25, 2020 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), a Rhode Island-based company and recognized leader in the field of computational vaccinology, today announced it has out-licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics ("EVT"), a New York-based company previously named EpiVax Oncology.
Scientists at EpiVax designed EPV-CoV-19 - a peptide-based, epitope-driven vaccine - utilizing their validated computational toolkit (iVAX), which enabled the selection of sequences representing all circulating SARS-CoV-2 genomes that will drive a T cell-mediated immune response, with the goal of providing recipients with immune system "body armor", reducing their risk of severe COVID-19 disease.
With in-licensing the COVID-19 vaccine program, EVT is broadening its pipeline and application of its platform beyond its clinical-stage personalized cancer vaccine program. The venture-backed company will provide an ideal environment for funding and development of EPV-CoV-19. The company recently re-organized its executive team in preparation for the pipeline expansion and is raising $3M to support the new program.
Having received a positive pre-IND response from the FDA, EVT is progressing to a clinical trial. It has begun GMP peptide production and is preparing the IND submission in parallel.
Michael Princiotta, CSO at EVT, said, "EVT is pleased to welcome the COVID-19 vaccine program into our pipeline. We are eager to apply our vaccine platform and fundraising experience to advance EPV-CoV-19 into clinical trials."
Annie De Groot, CEO/CSO and cofounder of EpiVax, said, "The EpiVax team has done a fantastic job in the preclinical research phase. We are confident that EPV-CoV-19 will be safe and effective for frontline healthcare workers. We look forward to working with EVT to accelerate its progress to Phase I and beyond."
About EpiVax: EpiVax has pioneered the use of in silico immunogenicity screening toolkits for therapeutics and vaccines. These toolkits, ISPRI and iVAX, are used for advancing product development at a global roster of companies. See the latest peer-reviewed publications at https://www.frontiersin.org/articles/10.3389/fimmu.2020.00442/full [https://c212.net/c/link/?t=0&l=en&o=2898784-1&h=12027929&u=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.00442%2Ffull&a=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.00442%2Ffull] and https://www.frontiersin.org/articles/10.3389/fimmu.2020.01301/full [https://c212.net/c/link/?t=0&l=en&o=2898784-1&h=2731707875&u=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.01301%2Ffull&a=https%3A%2F%2Fwww.frontiersin.org%2Farticles%2F10.3389%2Ffimmu.2020.01301%2Ffull] for more information about recent applications of EpiVax's in silico vaccine design and protein therapeutic immunogenicity assessment tools.
About EVT: EVT, founded in 2017, employs a world-leading technology, developed over 22 years by EpiVax, to design vaccines that aim to activate the body's T cells to cure or prevent disease in the host. EVT's pipeline includes a COVID-19 vaccine and a personalized bladder cancer vaccine.
Press Contact: Annie De Groot, MD CEO/CSO, EpiVax T : 401-272-2123 E: AnnieD@epivax.com
Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg [https://c212.net/c/link/?t=0&l=en&o=2898784-1&h=775455576&u=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F542055%2FEpiVax_Logo.jpg&a=https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F542055%2FEpiVax_Logo.jpg]